Wednesday, June 10, 2026

Patent intelligence · EP

EP 3144307

NEUE OXAZOL DERIVATEN ALS SYK KINASEHEMMER

granted A61K 31/ 506 A IA61K/31506A61K/31513A61K/315377
Status granted
Pipeline programs 6
Years to expiry 11
Applicant portfolio 25
Patent details — EP 3144307
Jurisdiction
EP
Status
granted
Grant date
Mar 22, 2017
Expiration
Mar 17, 2037
Applicant
AB SCIENCE [FR]
CPC classes
A61K 31/ 506 A I, A61K/31506, A61K/31513, A61K/315377
View on Google Patents ↗

Quick answer

EP 3144307 (NEUE OXAZOL DERIVATEN ALS SYK KINASEHEMMER) is held by AB SCIENCE [FR]. Status: granted. Granted Mar 22, 2017. Expires Mar 17, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
AB SCIENCE [FR]
Grant date
Expiration
Claims
CPC classes
A61K 31/ 506 A I, A61K/31506, A61K/31513, A61K/315377, A61P 35/ 00 A I, A61P 37/ 00 A I

More from AB SCIENCE [FR]

Related pharmaceutical patents in our USPTO index.

  1. WO 2025027051

    INHIBITEURS DE SPHINGOSINE-1-PHOSPHATE LYASE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES

    AB SCIENCE [FR] · Expires Feb 1, 2045

    granted
  2. WO 2024175803

    COMPOSÉS POUR LE TRAITEMENT DE MALADIES MYÉLOÏDES AVEC DES ANOMALIES CHROMOSOMIQUES

    AB SCIENCE [FR] · Expires Aug 24, 2044

    granted
  3. WO 2024146923

    INHIBITEURS DE POLYMÉRISATION DE TUBULINE

    AB SCIENCE [FR] · Expires Jul 6, 2044

    granted
  4. CN 117980330

    Homodimeric peptides and antibodies comprising same

    PAXTRADIA MAB SCIENCE AB · Expires Apr 28, 2044

    granted
  5. CA 3217490

    MASITINIB POUR LE TRAITEMENT DU CANCER DE LA PROSTATE RESISTANT A LA CASTRATION

    AB SCIENCE [FR] · Expires Nov 19, 2042

    granted
  6. WO 2022234069

    NOUVEAUX DÉRIVÉS DE 2-AMINOOXAZOLE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES INFECTIEUSES

    AB SCIENCE [FR] · Expires Nov 5, 2042

    granted
  7. CA 3201259

    MASITINIB POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    AB SCIENCE [FR] · Expires Jun 18, 2042

    granted
  8. CA 3174748

    UTILISATION DE MASITINIB POUR LE TRAITEMENT DE LA MALADIE A CORONAVIRUS 2019 (COVID-19)

    AB SCIENCE [FR] · Expires Oct 9, 2041

    granted

Frequently asked questions

What is US patent 3144307?

EP 3144307 (NEUE OXAZOL DERIVATEN ALS SYK KINASEHEMMER) is held by AB SCIENCE [FR]. Status: granted. Granted Mar 22, 2017. Expires Mar 17, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns EP 3144307?

AB SCIENCE [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does EP 3144307 expire?

Our index shows an expiration date of Mar 17, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.